Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q3 2017 · 10-Q
Revenue$1.28M$1.28M+7.0% vs Q3 2016 Net Income-$1.36M-$1.36MN/M vs Q3 2016 EPS Diluted-$0.02-$0.02N/M vs Q3 2016 Gross Profit$293,000+343.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,485,000N/M Free Cash Flowderived-$1,539,000N/M Margins · derivedGross margin22.9%+17.3 pt vs Q3 2016
Operating margin-108.3%+2.4 pt vs Q3 2016
Net margin-106.1%−6.3 pt vs Q3 2016
ended Mar 31, 2017 · filed May 10, 2017 · 40 d after period end